Cannara Biotech, Inc.

As of May 31, 2026, Cannara Biotech, Inc. carries a market capitalization of 164.97M, placing it among publicly traded companies globally. Its enterprise value stands at 180.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cannara Biotech, Inc.'s next confirmed earnings release is scheduled for November 24, 2026.

As of May 31, 2026, Cannara Biotech, Inc. has 98.78M shares outstanding.

As of May 31, 2026, Cannara Biotech, Inc. trades at a trailing price-to-earnings ratio of 14.62. The price-to-sales ratio is 1.35, and the price-to-book ratio stands at 1.31.

As of May 31, 2026, Cannara Biotech, Inc. trades at an EV/EBITDA multiple of 7.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Cannara Biotech, Inc. trades at an EV/FCF ratio of 24.68, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 180.16M versus a market cap of 164.97M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, Cannara Biotech, Inc. maintains a current ratio of 3.00, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.40, indicating elevated leverage, while an interest coverage ratio of 10.57 demonstrates strong ability to service its debt obligations.

Over the twelve months ended May 31, 2026, Cannara Biotech, Inc. posted a return on equity (ROE) of 9.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.96, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.07, useful for judging operating efficiency across full business cycles. The company generates approximately 259,587.83 in revenue per employee across its workforce of 452.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.29 indicates how many times Cannara Biotech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended May 31, 2026, Cannara Biotech, Inc. recorded 5.42M in income tax expense. That works out to an effective tax rate of 33.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 16.27M, leaving 10.86M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Cannara Biotech, Inc.'s stock has gained approximately 17.75% over the past 52 weeks. The 50-day moving average sits at 2.04, while the 200-day moving average is 1.86.

Over the twelve months ended May 31, 2026, Cannara Biotech, Inc. generated 117.33M in revenue and converted that into 10.86M in net income, yielding earnings per share of 0.11. EBITDA reached 25.41M, while operating income came in at 18.36M.

As of May 31, 2026, Cannara Biotech, Inc. holds 21.81M in cash and equivalents against 37.00M in total debt, resulting in a net debt position of 15.01M. Total book value stands at 125.85M, with working capital of 65.12M providing operational flexibility.

Cannara Biotech, Inc. produced 19.42M in operating cash flow over the twelve months ended May 31, 2026. After subtracting -13.72M in capital expenditures, free cash flow totaled 5.69M - equivalent to 0.06 per share.

Over the twelve months ended May 31, 2026, Cannara Biotech, Inc. posted a gross margin of 42.59, reflecting its pricing power and cost economics. The operating margin of 15.65 and net profit margin of 9.25 provide insight into operational efficiency.

Over the twelve months ended May 31, 2026, Cannara Biotech, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.53, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -2.32, meaning Cannara Biotech, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cannara Biotech, Inc.'s most recent stock split took place on February 13, 2023 with a 10:1 split ratio.

As of May 31, 2026, Cannara Biotech, Inc. has an Altman Z-Score of 2.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.